The decade's most triggering comedy
A teenager is suing a health care company and the doctors who put her on controversial puberty-blocking drugs at age 12 and removed her healthy breasts in a double-mastectomy surgery when she was just 13 years old, accusing them of “intentional fraud and concealment.”
Layla Jane, an 18-year-old detransitioner represented by attorney Harmeet Dhillon, claims in a letter of intent to sue that she was rushed into the life-altering medical services while she and her family were not properly informed of risks and other vital information, such as the rate of desistence for childhood gender dysphoria.
“Layla immediately started puberty blockers and testosterone at age 12, and had a double mastectomy at age 13,” the legal letter states.
“Two of Layla’s initial providers advised that per Kaiser’s official policies, Layla could not start cross-sex hormones until she was 16 and advised that surgery was not permissible until age 18,” the letter claims. “But, soon thereafter, Layla ended up in the hands of Dr. [Susanne E.] Watson, Dr. [Lisa Kristine] Taylor, and Dr. [Winnie Mao Yiu] Tong. These doctors immediately approved Layla for cross-sex hormones and a double mastectomy at ages 12-13, without performing an adequate evaluation and treatment of Layla’s extensive mental health co-morbidities.”
“I don’t think I should have been allowed to change my sex before I could legally consent to have sex,” Layla said during a Fox News appearance this past week. “I don’t think I’m better off for the experience, and I think transition just completely added fuel to the fire that was my pre-existing conditions.”
The letter alleged that doctors “pushed” the child and her parents down the “transition path, engaging in intentional, malicious, and oppressive concealment of important information and false representations.”
“This concealment included, among other things, the lack of adequate clinical research supporting this treatment, particularly for 12-year-old girls; the existence of high-quality clinical research contra-indicating treatment; the 80-90% desistence rates for childhood gender dysphoria; and the significant possibility of detransition and regret,” the letter charges. “The fraudulent misrepresentations included, among other things, falsely representing that Layla’s gender dysphoria and co-morbid mental health symptoms would not resolve without imitation sex change transition, falsely representing that Layla presented an increased risk of suicide unless she transitioned, and presenting Layla’s parents with the false dilemma that: ‘would they rather have a live son, or a dead daughter?'”
Chloe Cole, another detransitioned 18-year-old woman, announced last month the first official lawsuit in the U.S. against the same health care group, which, too, facilitated her medical gender transition as a minor.